Date: 2015-11-05
Type of
information: Presentation of results at a congress
phase:
Announcement: presentation of results at the 57th American Society of Hematology (ASH) Annual Meeting in Orlando
Company: Cellectis (France) Great Ormond Street Hospital (GOSH) (UK) University College London (UCL) (UK)
Product: UCART19
Action
mechanism:
- cell therapy/immunotherapy product/gene therapy/CAR-T cell therapy. UCART19 are allogeneic engineered chimeric antigen teceptor (CAR+) T-cells. Servier has an option under the collaboration agreement to acquire the exclusive rights to further develop and commercialize UCART19.
Disease: refractory relapsed Acute Lymphoblastic Leukemia (ALL) following mismatched allogeneic stem cell transplantation
Therapeutic
area: Cancer - Oncology
Country: UK
Trial
details:
Latest
news:
- • On November 5, 2015, Cellectis announced that Great Ormond Street Hospital (GOSH) and University College London (UCL) will present encouraging data from a first in man clinical use of UCART19, at the 57th American Society of Hematology (ASH) Annual Meeting in Orlando during the poster session. GOSH has treated in June 2015 a young leukemia patient under a special license from the Medicines & Healthcare products Regulatory Agency (MHRA) with Cellectis’ TALEN® gene edited allogeneic UCART19 product candidate because no other therapies were available for refractory relapsed Acute Lymphoblastic Leukemia (ALL) following mismatched allogeneic stem cell transplantation. In response to an unsolicited request from Professor Waseem Qasim, Consultant Immunologist at GOSH and Professor of Cell and Gene Therapy at University College London (UCL) Institute of Child Health, Cellectis gave its approval for the use of its UCART19 product candidate and technologies under GOSH’s "Specials" license and responsibility, for the particular clinical needs of that individual patient.
Is
general: Yes
